Encouraging that one of the Directors is buying and explains the higher than normal volumes over the last 2 days.This gives confidence for the future of the company
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling